Rob helps clients raise capital, navigate risk, and tell a story through filings and disclosures over the long term. For example, he represented Loxo Oncology in its IPO, multiple follow-on offerings and its $8 billion acquisition by Eli Lilly. He has also represented Dexcom, a leader in continuous glucose monitoring, for more than 15 years, from its IPO in 2005 to numerous public and private offerings of equity and debt. Rob is committed to a company’s myriad legal needs through its full lifecycle.

Ranked as a top capital markets lawyer by Chambers USA and Chambers Global, Rob is regularly sought after for his thought leadership. He is a lead author of the firm’s Technology and Life Sciences IPO Survey and co-chairs the Practising Law Institute’s How to Prepare an Initial Public Offering 2019 program.